6939.Two
6939.TWO operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the development, production, and distribution of pharmaceutical products.
Business. 6939.TWO operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the development, production, and distribution of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
6939.TWO operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the development, production, and distribution of pharmaceutical products.
The company maintains a conservative capital structure, with a debt-to-equity ratio of 0.19, indicating a strong equity position relative to its liabilities. Its liquidity position is characterized as low, with cash and equivalents amounting to 307,325,000 TWD, which is a significant portion of its total assets. However, the company reported negative operating cash flow of -9,741,000 TWD, suggesting potential challenges in generating cash from its core operations.
In terms of profitability, the company's financial performance is not explicitly detailed in the provided data. However, the low debt-to-equity ratio suggests a conservative approach to leveraging debt, which may support financial stability. The company's total equity of 1,164,104,000 TWD indicates a solid equity base, which can be a buffer against financial downturns.
The company's revenue is not segmented by geographic regions or product lines in the provided data, making it difficult to assess revenue concentration or geographic exposure. However, the company's primary activity in pharmaceuticals suggests a potential focus on a specific market or product line.
The company's growth trajectory is not clearly defined in the provided data. The financial snapshot does not include historical revenue data or future projections. The capital expenditure of -225,419,000 TWD indicates a significant investment in long-term assets, which could be a sign of expansion or modernization efforts.
The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's low debt-to-equity ratio and substantial cash reserves suggest a strong liquidity position. However, the negative operating cash flow could pose a challenge in maintaining liquidity in the long term.
There are no recent events or filings mentioned in the provided data that would impact the company's operations or financial position. The absence of such events suggests a stable operating environment, but it also means that there is no new information to assess the company's current performance or future prospects.
- The company has a conservative capital structure with a low debt-to-equity ratio of 0.19.
- The company's liquidity position is characterized as low, with significant cash reserves but negative operating cash flow.
- The company's financial performance is not explicitly detailed, but its strong equity base suggests financial stability.
- The company's growth trajectory is not clearly defined, but significant capital expenditure indicates potential expansion or modernization efforts.
- The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- 6939.TWO Market data — financials · 2026-05-27
Ownership & reference
Leadership
- Tatung YuanChairman of the Board, Chief Executive Officer